Treatment of negative and cognitive symptoms (Q34108164)

31 July 2017

1 reference

title

Treatment of negative and cognitive symptoms (English)

1 reference

31 July 2017

Javitt DC

1

1 reference

PubMed ID

11122902

31 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Current Psychiatry Reports

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

1

1 reference

31 July 2017

25-30

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-999-0007-z

31 July 2017

0 references

cites work

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Structural evaluation of the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Effects of clozapine for non-treatment-resistant patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-999-0007-Z

Generalized cognitive deficits in schizophrenia: a study of first-episode patients.

21 January 2018

1 reference

12 December 2020

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

12 December 2020

Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction.

1 reference

12 December 2020

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

12 December 2020

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

12 December 2020

Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.

1 reference

12 December 2020

Normal time course of auditory recognition in schizophrenia, despite impaired precision of the auditory sensory ("echoic") memory code

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

12 December 2020

The NMDA antagonist model for schizophrenia: promise and pitfalls.

1 reference

12 December 2020

Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes.

1 reference

12 December 2020

High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum.

1 reference

12 December 2020

Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

1 reference

12 December 2020

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

1 reference

12 December 2020

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response

1 reference

12 December 2020

Impaired categorical perception of synthetic speech sounds in schizophrenia

1 reference

12 December 2020

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

1 reference

12 December 2020

Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses.

1 reference

12 December 2020

Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis.

1 reference

12 December 2020

Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up

1 reference

12 December 2020

Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome

1 reference

12 December 2020

Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS)

1 reference

12 December 2020

The effects of clozapine on cognitive functioning in schizophrenia

1 reference

12 December 2020

Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group.

1 reference

12 December 2020

Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

1 reference

12 December 2020

Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.

1 reference

12 December 2020

The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures

1 reference

12 December 2020

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

12 December 2020

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

1 reference

12 December 2020

The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis.

1 reference

12 December 2020

Effects of clozapine on auditory event-related potentials in schizophrenia

1 reference

12 December 2020

10.1007/S11920-999-0007-Z

Identifiers

DOI

1 reference

PubMed ID

11122902

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11122902